trending Market Intelligence /marketintelligence/en/news-insights/trending/fcFc1RHb7-04KTrvOPPi8Q2 content esgSubNav
In This List

Biogen Idec ends collaborative agreement with Proteostasis Therapeutics

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Biogen Idec ends collaborative agreement with Proteostasis Therapeutics

Proteostasis Therapeutics Inc. is no longer in a partnership to develop treatments for Alzheimer's and Parkinson's diseases with Biogen Idec New Ventures Inc.

Biogen Idec terminated the partnership after Proteostasis failed to produce a lead compound that could be advanced as a drug candidate.